|
|
|
|
Adjunctive cabergoline therapy significantly improved mean motor scores at the time of each standardized serial examination,from 30 minutes to 6 hours after the administration of test doses of medications.Significant motor score improvement was also measured 24 hours after the last cabergoline dose was administered,suggesting a very long-acting antiparkinsonian effect.Mean dyskinesia scores were slightly but nonsignificantly elevated.Diary cared"off-time"was improved by 42%,whereas the levodopa dosage was reduced by 18%.Only three patients dropped out(7% of the total),which contrasts with much higher dropout rates owing to adverse events in previous clinical trials of other antiparkinsonian dopamine agonists.Cabergoline improved motor control in patients with Parkinson's disease who were experiencing clinical fluctuations.Possible advantages of this medication include an extended clinical response (persisting to 24 hours),tolerability,and ease of use(once per day administration). |
|